Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
exenatide
exenatide
- Formulary Miscellaneous Program Formulary
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Bydureon BCise | DEVICE, SUBCUTANEOUS | 2 mg/0.85 mL | ||||
| Bydureon | POWDER FOR INJECTION, EXTENDED RELEASE, SUBCUTANEOUS | 2 mg | ||||
| Bydureon | SOLUTION, SUBCUTANEOUS | 2 mg | ||||
| Byetta Prefilled Pen | SOLUTION, SUBCUTANEOUS | 10 mcg/0.04 mL, 5 mcg/0.02 mL |
Last updated: Dec. 22, 2023
- Black Box Warning: Extended Release Injection: Risk of thyroid c-cell tumors
- Formulary, Not Routinely Stocked: Byetta - 5 mcg/0.02 mL prefilled 1.2 mL pen and 10 mcg/0.04 mL prefilled 2.4 mL pen
Bydureon medication guide
Bydureon Bcise medication guide
Byetta medication guide
Byetta Prefilled Pen: Byetta is a MULTI-use item. Make sure that only ONE pen is dispensed at a time AND it is TAMPER TAPED. Each pen should be dispensed in a plastic bag with the bright green (or other neon-colored) label attached that says:
BYETTA is a MULTI-use item
Store at patient bedside.
Discard Date:__/__/__ (30 days after dispensing)
Bydureon is a long acting form of the drug dosed once weekly. Non-formulary, not stocked. Defer use to outpatient setting. Inpatient may use their own supply if judged necessary.
Bydureon BCise is non-formulary. Inpatients may use their own supply if needed.
Reviewed: July 27, 2005 (BYETTA), and May 22, 2012 (BYDUREON), and 28 July 2015 (Bydureon), and 27 March 2018 (Bydureon BCise)